<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04946617</url>
  </required_header>
  <id_info>
    <org_study_id>9.2.2017-30</org_study_id>
    <nct_id>NCT04946617</nct_id>
  </id_info>
  <brief_title>Chlorhexidine and Essential Oil Mouthwashes on Human Beta-Defensin 2 (hbD2) and Kathelicidin (LL-37) Saliva Levels</brief_title>
  <acronym>hbD2</acronym>
  <official_title>The Effect of Chlorhexidine and Essential Oil Mouthwashes on Human Beta-Defensin 2 (hbD2) and Kathelicidin (LL-37) Saliva Levels</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Istanbul Medeniyet University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Istanbul Medeniyet University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Recent studies have shown that while mouthwashes exhibit antimicrobial properties against&#xD;
      bacteria and their products, at the same time showing the cytotoxic effect on living cells in&#xD;
      the mouth.29 To the best of our knowledge, there is no information about the toxicity effect&#xD;
      of these two mouthwashes, which are highly preferred, on antimicrobial peptides secreted from&#xD;
      the oral epithelium. Therefore, our aim in this study is to evaluate the effect of&#xD;
      chlorhexidine and essential oil mouthwash on hBD2 and LL-37 in saliva.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Periodontal health continues with a balanced interaction of the oral microflora with the host&#xD;
      defense line.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 20, 2021</start_date>
  <completion_date type="Anticipated">December 20, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 20, 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>6 Months</target_duration>
  <primary_outcome>
    <measure>Rate of periodontal parametres changes</measure>
    <time_frame>6 Months</time_frame>
    <description>Incidence of Gingivitis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of periodontal parametres changes</measure>
    <time_frame>6 Months</time_frame>
    <description>Incidence of Periodontitis</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Mouth and Tooth Diseases</condition>
  <condition>Periodontal Diseases</condition>
  <condition>Gingivitis</condition>
  <arm_group>
    <arm_group_label>H group</arm_group_label>
    <description>healthy periodontium, BOP at \20 % of the sites and no sites with probing depth (PD) [3 mm and clinical attachment level (CAL) [2 mm or alveolar bone loss (N = 20, 12 males, 8 females, mean age: 33.38</description>
  </arm_group>
  <arm_group>
    <arm_group_label>G group</arm_group_label>
    <description>gingivitis, BOP at ≥20 % of the sites and no sites with PD and CAL [3 mm or bone loss (N = 20, 6 males, 14 females, mean age: 32.35);</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CP group</arm_group_label>
    <description>chronic periodontitis, ≥4 teeth in each jaw with PD of ≥5 mm, CAL of C4 mm, BOP at [≥80 % of the proximal sites and radiographic evidence of interproximal bone loss</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>undefined</intervention_name>
    <description>Rinsing with mouthwashes</description>
    <arm_group_label>CP group</arm_group_label>
    <arm_group_label>G group</arm_group_label>
    <arm_group_label>H group</arm_group_label>
    <other_name>Mouthwash Product</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The sample size was calculated using (power of 80%). The present study included 40 patients&#xD;
        per group (total of 120) to have a power &gt;80%.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. systemically healthy,&#xD;
&#xD;
          2. presence of ≥20 natural teeth,&#xD;
&#xD;
          3. agreement to participate in the study .&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. known systemic illness,&#xD;
&#xD;
          2. smoking habit,&#xD;
&#xD;
          3. pregnancy/ lactation,&#xD;
&#xD;
          4. long-term use of anti-inflammatory drugs.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Mustafa C Yavuz, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Istanbul Medeniyet University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mustafa C Yavuz, PhD</last_name>
    <phone>+905056429856</phone>
    <email>muscyz111@gmail.com</email>
  </overall_contact>
  <reference>
    <citation>Van Dyke TE. Pro-resolving mediators in the regulation of periodontal disease. Mol Aspects Med. 2017 Dec;58:21-36. doi: 10.1016/j.mam.2017.04.006. Epub 2017 May 18. Review.</citation>
    <PMID>28483532</PMID>
  </reference>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 14, 2021</study_first_submitted>
  <study_first_submitted_qc>June 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 1, 2021</study_first_posted>
  <last_update_submitted>June 23, 2021</last_update_submitted>
  <last_update_submitted_qc>June 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Istanbul Medeniyet University</investigator_affiliation>
    <investigator_full_name>Mustafa Cihan Yavuz</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Periodontitis</keyword>
  <keyword>Gingivitis</keyword>
  <keyword>Mouthwashes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gingivitis</mesh_term>
    <mesh_term>Periodontal Diseases</mesh_term>
    <mesh_term>Tooth Diseases</mesh_term>
    <mesh_term>Stomatognathic Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

